Atreca, Inc. Logo

Atreca, Inc.

BCEL

(1.2)
Stock Price

0,09 USD

-360.93% ROA

-195.22% ROE

-0.09x PER

Market Cap.

8.951.080,00 USD

11.91% DER

0% Yield

-36150.95% NPM

Atreca, Inc. Stock Analysis

Atreca, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Atreca, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.19x), the stock offers substantial upside potential at a bargain price.

2 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

3 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

Negative ROE (-117.24%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-71.4%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 DER

The stock is burdened with a heavy load of debt (139%), making it financially unstable and potentially risky for investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Atreca, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Atreca, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Atreca, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Atreca, Inc. Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Atreca, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 24.873.000
2018 32.513.000 23.5%
2019 54.726.000 40.59%
2020 62.045.000 11.8%
2021 78.349.000 20.81%
2022 66.829.000 -17.24%
2023 41.628.000 -60.54%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Atreca, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 4.562.000
2018 7.060.000 35.38%
2019 17.845.000 60.44%
2020 26.834.000 33.5%
2021 31.954.000 16.02%
2022 31.466.000 -1.55%
2023 21.544.000 -46.05%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Atreca, Inc. EBITDA
Year EBITDA Growth
2017 -26.359.000
2018 -36.489.000 27.76%
2019 -67.224.000 45.72%
2020 -83.931.000 19.91%
2021 -109.245.000 23.17%
2022 -96.708.000 -12.96%
2023 25.780.000 475.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Atreca, Inc. Gross Profit
Year Gross Profit Growth
2017 0
2018 0 0%
2019 -122.000 100%
2020 -22.000 -454.55%
2021 -77.000 71.43%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Atreca, Inc. Net Profit
Year Net Profit Growth
2017 -27.527.000
2018 -37.940.000 27.45%
2019 -67.484.000 43.78%
2020 -86.335.000 21.83%
2021 -109.326.000 21.03%
2022 -90.525.000 -20.77%
2023 -144.860.000 37.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Atreca, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 -12
2018 -12 -9.09%
2019 -4 -175%
2020 -3 -100%
2021 -3 0%
2022 -2 0%
2023 -4 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Atreca, Inc. Free Cashflow
Year Free Cashflow Growth
2017 -26.473.000
2018 -36.464.000 27.4%
2019 -61.985.000 41.17%
2020 -71.697.000 13.55%
2021 -96.010.000 25.32%
2022 -81.606.000 -17.65%
2023 -17.277.000 -372.34%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Atreca, Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -25.096.000
2018 -34.700.000 27.68%
2019 -58.538.000 40.72%
2020 -66.671.000 12.2%
2021 -60.920.000 -9.44%
2022 -80.721.000 24.53%
2023 -17.216.000 -368.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Atreca, Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 1.377.000
2018 1.764.000 21.94%
2019 3.447.000 48.83%
2020 5.026.000 31.42%
2021 35.090.000 85.68%
2022 885.000 -3864.97%
2023 61.000 -1350.82%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Atreca, Inc. Equity
Year Equity Growth
2017 -56.567.000
2018 117.016.000 148.34%
2019 186.952.000 37.41%
2020 242.057.000 22.77%
2021 154.929.000 -56.24%
2022 78.406.000 -97.6%
2023 10.759.000 -628.75%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Atreca, Inc. Assets
Year Assets Growth
2017 36.112.000
2018 121.684.000 70.32%
2019 195.715.000 37.83%
2020 272.064.000 28.06%
2021 200.057.000 -35.99%
2022 155.030.000 -29.04%
2023 26.342.000 -488.53%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Atreca, Inc. Liabilities
Year Liabilities Growth
2017 92.679.000
2018 4.668.000 -1885.41%
2019 8.763.000 46.73%
2020 30.007.000 70.8%
2021 45.128.000 33.51%
2022 76.624.000 41.1%
2023 15.583.000 -391.72%

Atreca, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-2.42
Price to Earning Ratio
-0.09x
Price To Sales Ratio
0x
POCF Ratio
-0.14
PFCF Ratio
-0.14
Price to Book Ratio
0.83
EV to Sales
0
EV Over EBITDA
0.06
EV to Operating CashFlow
0.05
EV to FreeCashFlow
0.05
Earnings Yield
-10.69
FreeCashFlow Yield
-7.3
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
3.85
Graham NetNet
0.16

Income Statement Metrics

Net Income per Share
-2.42
Income Quality
0.67
ROE
-1.95
Return On Assets
-3.61
Return On Capital Employed
-5.58
Net Income per EBT
0.97
EBT Per Ebit
1.63
Ebit per Revenue
-228.44
Effective Tax Rate
-0.18

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-24.2
Operating Profit Margin
-228.44
Pretax Profit Margin
-371.7
Net Profit Margin
-361.51

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.65
Free CashFlow per Share
-1.66
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-0.05
Return on Invested Capital
-5.31
Return on Tangible Assets
-3.61
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,54
Book Value per Share
0,27
Tangible Book Value per Share
0.27
Shareholders Equity per Share
0.27
Interest Debt per Share
-0.04
Debt to Equity
0.12
Debt to Assets
0.05
Net Debt to EBITDA
0.23
Current Ratio
1.58
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.12
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-5680000
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Atreca, Inc. Dividends
Year Dividends Growth

Atreca, Inc. Profile

About Atreca, Inc.

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

CEO
Mr. John A. Orwin M.B.A.
Employee
90
Address
835 Industrial Road
South San Francisco, 94070

Atreca, Inc. Executives & BODs

Atreca, Inc. Executives & BODs
# Name Age
1 Mr. Rick Ruiz
Principal Accounting Officer
70
2 Ms. Courtney J. Phillips J.D.
General Counsel & Corporate Secretary
70
3 Mr. John A. Orwin M.B.A.
President, Chief Executive Officer, Director & Principal Financial Officer
70
4 Dr. Tito A. Serafini Ph.D.
Founder & Director
70
5 Roger Richard Ruiz
Vice President of Finance
70

Atreca, Inc. Competitors